Cash Position
The company has 12.0 months of cash left based on the quarterly cash burn of $44.70 M and estimated current cash of $178.74 M
Commentary on Financial Condition
The company has incurred significant losses since its inception, with an accumulated deficit of approximately $2.0 billion as of December 31, 2024, primarily due to research and development expenses. Despite generating revenues from strategic collaborations and sales of its approved drug products, the company expects to continue incurring substantial research and development costs and will need to generate significantly higher revenues to achieve profitability. The company believes its current cash and investment balances, along with expected revenues, will be sufficient to fund operations for at least the next 12 months, but it may need to seek additional financing through collaborations, equity or debt securities, or credit arrangements if cash on hand is insufficient., Filed At: 2025-03-07
Former Symbols
Nasdaq Compliance
Date
Deficiency
Market
Status
Notes
Jan 3, 2025
Bid Price
NGS
OPEN
Lexicon Pharmaceuticals received a notice from Nasdaq on January 7, 2025, indicating non-compliance with the minimum bid price requirement of $1 per share. The company has until July 2, 2025, to regain compliance by maintaining a closing bid price of at least $1 for ten consecutive business days, or it may seek an additional 180-day compliance period to avoid potential delisting. Filed At: 2025-01-07.
Previous Splits
Date
Split
Shelf
Title | Raisable Amt | Offering Amt | Amt Sold Last 12 Mos | Float | 60 Day High | Price to Exceed Baby Shelf | Float Value | Exp Date | Effective date | |
|---|---|---|---|---|---|---|---|---|---|---|
August 2024 SHELF | $200,000,000.00 | $200.00 M | 0 | 178.78 M | 200 | 0.42 | 35.76 B | 8/16/2027 | 8/16/2024 | |
EXPIRED-August 2021 SHELF | Offering amount: $200,000,000.00 | $200,000,000.00 | $200.00 M | 0 | 178.78 M | 200 | 0.42 | 35.76 B | 9/15/2024 | 9/15/2021 |
ATM
Title | ATM Remaining | Offering Amt | Exp Date | Shr Amt | Bank | Date | Type | |
|---|---|---|---|---|---|---|---|---|
EXPIRED-ATM | Offering amount: $75,000,000 | $75,000,000.00 | $75.00 M | 9/15/2024 | - | - | Dec 29, 2023 | 424B5 |
Warrants
Title | Registered | Remaining Warrants | Ex Price | Cost Basis | Total Warrants | Owners | Bank | Price Protection | Details | Exercisable Date | Expiration Date | Filed Date | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
December 2022 Warrants | Not Registered | 420,673 | $2.08 | - | 420,673 | Oxford Finance | - | Dec 30, 2027 | Dec 30, 2022 | ||||
March 2022 Warrants | Not Registered | 407,952 | $2.38 | - | 407,952 | Oxford Finance | - | - | Mar 1, 2022 |
Completed Offerings
Title | Offering Amt | Shr Amt | Share Price | Warrants | Bank | Owners | Date | Type | |
|---|---|---|---|---|---|---|---|---|---|
PRIVATE PLACEMENT | $250.00 M | 2.30 M | $108.50 | - | - | Invus, L.P. | Mar 11, 2024 | 8-K | |
DEBT OFFERING, WARRANT EXERCISE | $50.00 M | - | - | 183.82 k | - | Oxford Finance LLC | Jun 28, 2023 | 8-K | |
REGISTERED OFFERING | $62.20 M | 23.92 M | $2.60 | - | - | - | Jun 1, 2023 | 424B5 | |
DEBT OFFERING | $25.00 M | - | - | 224.13 k | - | Oxford Finance LLC | Jan 4, 2023 | 8-K | |
REGISTERED OFFERING | $42.11 M | 16.84 M | $2.50 | - | - | - | Jul 29, 2022 | 424B5 | |
DEBT OFFERING | $150.00 M | - | - | - | - | Oxford Finance LLC | Mar 17, 2022 | 8-K |